Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant

Seongseok Yun, MDPhD, Onyee Chan, MD, Daniel Kerr, MDPhD, Nicole D. Vincelette, PhD, Afshan Idrees, MD MPH, Qianxing Mo, PhD, Kendra Sweet, MD, Jeffrey E. Lancet, MD, Mohamed A kharfan-Dabaja, MDMBA, Ling Zhang, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-133391

Published: 2020

Journal Articles

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Seongseok Yun, MDPhD, David Gajzer, MD, Najla Al Ali, M.Sc, Nicole D. Vincelette, PhD, Pukhraz Basra, MBBS, Chetasi Talati, MD, Andrew T. Kuykendall, MD, Eric Padron, MD, Kendra Sweet, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, David A. Sallman, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137116

Published: 2020

Journal Articles

Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Alan F List, MD, Eric Padron, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 3912.

https://doi.org/10.1182/blood.V130.Suppl_1.3912.3912

Published: 2017

Journal Articles

Fluorescence in Situ Hybridization (FISH) Frequently Upstages Risk Estimates for MDS Patients with Normal Metaphase Karyotype

Rami S. Komrokji, MD, Hanadi Ramadan, BA, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD, Alan F List, MD

Blood (2017) 130 (Supplement 1): 4247.

https://doi.org/10.1182/blood.V130.Suppl_1.4247.4247

Published: 2017

Journal Articles

Outcomes in Older Adults (age ≥ 70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype

Blood (2017) 130 (Supplement 1): 1412.

https://doi.org/10.1182/blood.V130.Suppl_1.1412.1412

Published: 2017

Journal Articles

Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age ≥70) Is Karyotype Dependent

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Alan F. List, MD, Eric Padron, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Jeffrey E. Lancet, MD, Kendra Sweet, MD

Blood (2017) 130 (Supplement 1): 1413.

https://doi.org/10.1182/blood.V130.Suppl_1.1413.1413

Published: 2017

Journal Articles

Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy

Gail J. Roboz, MD, Stephen A. Strickland, MD MSCI, Mark R. Litzow, MD, Andrew Dalovisio, MD, Alexander E. Perl, MD, Gaetano Bonifacio, MD, Kelly Haines, Alysha Barbera, Das Purkayastha, Kendra Sweet, MD

Blood (2017) 130 (Supplement 1): 1338.

https://doi.org/10.1182/blood.V130.Suppl_1.1338.1338

Published: 2017

Journal Articles

Outcome of Myelodysplastic Syndrome Patients with TP53 Mutation Treated with Hypomethylating Agents

Rami S. Komrokji, MD, David A Sallman, MD, Najla Al Ali, M.Sc, Eric Padron, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD, Alan F List, MD

Blood (2017) 130 (Supplement 1): 1687.

https://doi.org/10.1182/blood.V130.Suppl_1.1687.1687

Published: 2017

Journal Articles

Effect of NPM1 Mutation on Prognosis and Therapeutic Efficacy in Patients Aged ≥70 Years with Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2676.

https://doi.org/10.1182/blood.V130.Suppl_1.2676.2676

Published: 2017

Journal Articles

Defining Acute Myeloid Leukemia Ontogeny in Older Patients

Megan Melody, BA, MS, David A Sallman, MD, Najla Al Ali, M.Sc, Hanadi Ramadan, BA, Ling Zhang, MD, Eric Padron, MD, Kendra Sweet, MD, Martine Extermann, MD, Alan F List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2017) 130 (Supplement 1): 2594.

https://doi.org/10.1182/blood.V130.Suppl_1.2594.2594

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality

Fluorescence in Situ Hybridization (FISH) Frequently Upstages Risk Estimates for MDS Patients with Normal Metaphase Karyotype

Outcomes in Older Adults (age ≥ 70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype

Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age ≥70) Is Karyotype Dependent

Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy

Outcome of Myelodysplastic Syndrome Patients with TP53 Mutation Treated with Hypomethylating Agents

Effect of NPM1 Mutation on Prognosis and Therapeutic Efficacy in Patients Aged ≥70 Years with Acute Myeloid Leukemia

Defining Acute Myeloid Leukemia Ontogeny in Older Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only